Caught in an instant firestorm over the $89,000 list price for its new Duchenne muscular dystrophy (DMD) drug, Marathon Pharmaceuticals LLC is doing some unprecedented backtracking, as it pauses the commercialization of Emflaza in the U.S. to give it more time to discuss access to the drug with the DMD community.